Moderna stock jumps 12% after $1.9 billion 2025 sales view — what investors watch next
New York, January 13, 2026, 11:31 EST — Regular session Moderna shares were up $3.97, or 11.7%, at $37.81 by late morning in New York, lifting the vaccine maker to one of the stronger movers in biotech trading. The bounce comes as investors try to pin down what “post-pandemic Moderna” looks like — smaller, more volatile, and still dependent on seasonal vaccine demand that can shift fast. The company’s early look at 2025 is being read as a test of whether the slide has finally slowed. Moderna said it expects about $1.9 billion in 2025 sales, near the top end